The Technical Analyst
Brainsway Ltd. [BWAY]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Brainsway Ltd. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.67% $4.87
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 81.02 mill |
| EPS: | -0.460 |
| P/E: | -10.59 |
| Earnings Date: | May 29, 2024 |
| SharesOutstanding: | 16.64 mill |
| Avg Daily Volume: | 0.111 mill |
| RATING 2024-04-19 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.59 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -10.59 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.42 - 5.14 ( +/- 7.47%) |
| ATR Model: 14 days |
Forecast:
16:00 - $4.87
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.87
Forecast 2: 16:00 - $4.87
Forecast 3: 16:00 - $4.87
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.87 (1.67% ) |
| Volume | 0.0414 mill |
| Avg. Vol. | 0.111 mill |
| % of Avg. Vol | 37.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BWAY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:20 | sell | $6.08 | N/A | Active |
|---|
BWAY
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Latest Press Releases
2024-04-04 08:00:00 - Press Release
Brainsway Announces Published Review Results Highlighting Potential Of Deep Tms™ To Treat Parkinson's Disease
Clinical data from multiple trials showed improvements in both motor and non-motor symptoms clinical data from multiple trials showed improvements in both motor and non-motor symptoms
2024-03-18 07:30:00 - Press Release
Brainsway Broadens Partnership With Katie's Way Plus Through Order Of An Additional 18 Deep Tms™ Systems
Katie's way provides lifesaving mental health treatment nationally with a focus on servicemembers, veterans, and their families katie's way provides lifesaving mental health treatment nationally with a focus on servicemembers, veterans, and their families
2024-03-06 07:30:00 - Press Release
Brainsway Reports Fourth Quarter And Full-year 2023 Financial Results And Operational Highlights
Generated record revenues with robust 50% year-over-year revenue growth in q4 2023; generated positive quarterly net income
2024-02-21 08:00:00 - Press Release
Brainsway To Report Fourth Quarter And Full Year 2023 Financial Results On March 6, 2024
Burlington, mass. and jerusalem, feb. 21, 2024 (globe newswire) -- brainsway ltd. (nasdaq & tase: bway) (“brainsway” or the “company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the u.s. financial markets on wednesday, march 6, 2024. the company will host a conference call and webcast at 8:30 am eastern time to discuss the results and provide an update on business operations.
2024-01-10 07:30:00 - Press Release
Brainsway Initiates Clinical Evaluation Of Rotational Field “deep Tms 360°™” Technology
Burlington, mass. and jerusalem, jan. 10, 2024 (globe newswire) -- brainsway ltd. (nasdaq & tase: bway) (“brainsway” or the “company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be clinically evaluating an innovative stimulation technology in two new feasibility trials.
Latest News
2024-03-27 10:36:07 - Zacks Investment Research
After Plunging -13.63% in 4 Weeks, Here's Why the Trend Might Reverse for Brainsway (BWAY)
Brainsway (BWAY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2024-03-18 13:01:05 - Zacks Investment Research
All You Need to Know About Brainsway Ltd. Sponsored ADR (BWAY) Rating Upgrade to Buy
Brainsway Ltd. Sponsored ADR (BWAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
2024-03-17 14:58:21 - InvestorPlace
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.
2024-03-11 11:00:17 - Zacks Investment Research
Best Momentum Stocks to Buy for March 11th
BWAY, WILYY and CRH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 11, 2024.
2024-03-11 08:06:03 - Zacks Investment Research
New Strong Buy Stocks for March 11th
BWAY, WILLY, IDCC, BRKL and SBSI have been added to the Zacks Rank #1 (Strong Buy) List on March 11, 2024.
2024-03-05 09:21:06 - Zacks Investment Research
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.
2024-02-21 08:00:00 - GlobeNewsWire
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
2024-02-06 15:51:41 - InvestorPlace
7 High-Growth Stocks to Snag for Spectacular Returns in 2024
In the stock market, pursuing high-growth stocks becomes a compelling venture, akin to searching for pearls in the vast sea of possibilities. The year 2024 unfolds with promises of prosperity and strategic opportunities, and within this realm, seven stocks emerge as yielders of potential riches.
2024-01-25 08:32:27 - InvestorPlace
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotech, offers exciting disruptive solutions with the potential to expand to market caps worth trillions! With new catalysts such as artificial intelligence and quantum computing offering methods to unlock complicated data sets to hasten drug development pipelines, it's no wonder that this market has a projected compound annual growth rate of 13.96% from 2024 to 2023.
2024-01-15 09:01:21 - Zacks Investment Research
5 Stocks With Recent Price Strength in a Volatile Market
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are VTSI, USAP, TAST, BWAY, VIRC.